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Abstract: Pre-clinical cell and animal nutrigenomic studies have long suggested the modulation of
the transcription of multiple gene targets in cells and tissues as a potential molecular mechanism
of action underlying the beneficial effects attributed to plant-derived bioactive compounds. To try
to demonstrate these molecular effects in humans, a considerable number of clinical trials have
now explored the changes in the expression levels of selected genes in various human cell and
tissue samples following intervention with different dietary sources of bioactive compounds. In this
review, we have compiled a total of 75 human studies exploring gene expression changes using
quantitative reverse transcription PCR (RT-qPCR). We have critically appraised the study design and
methodology used as well as the gene expression results reported. We herein pinpoint some of the
main drawbacks and gaps in the experimental strategies applied, as well as the high interindividual
variability of the results and the limited evidence supporting some of the investigated genes as
potential responsive targets. We reinforce the need to apply normalized procedures and follow
well-established methodological guidelines in future studies in order to achieve improved and
reliable results that would allow for more relevant and biologically meaningful results.
Keywords: health effects; plant food bioactives; mRNA levels; RT-qPCR; human tissues;
interindividual variability
1. Introduction
Plant foods and many of their derived products (beverages, oils, extracts) contain a variety of
essential and non-essential bioactive compounds (mostly fatty acids and phytochemicals) which have
been endorsed with a variety of biological activities that can contribute to the promotion of a healthy
status and/or the prevention of various chronic and inflammatory disorders (e.g., cancer, obesity,
cardiovascular and neurological diseases) [1,2]. A large number of pre-clinical studies have repeatedly
shown that exposure of human cultured cells or animal models to some of these bioactive compounds
and/or some of their derived metabolites is associated with changes in the levels of a wide array
of molecular targets which suggest that this might constitute one of the mechanisms of action by
which dietary bioactive compounds exert their beneficial effects [3]. Many of these compounds have
been shown to exert anti-proliferative [4], anti-inflammatory [5] and anti-obesity [6] effects as well as
cardiovascular [7] and neurological [8] protection, in association with changes in the expression of
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genes implicated in cancer development (TP53, CTNNB1, MYC, MMPs), apoptosis (CASPs, BAX, BCL2),
cell cycle control (CDKN1A, CDKN2A), transcription (NFKB, AKTs, STATs, NFE2L2, JUN), cell adhesion
(VCAM1, ICAM1), inflammation (TNF, ILs, NOS2, PTGS2, CCL2), xenobiotic metabolism (CYPs, UGTs,
SULTs), energy metabolism (PRKAs (AMPK), PPARs, PPARGC1A, UCPs), transporters (SLC2A4), and/or
redox processes (NOS2, GPXs, GSTs, SODs, CAT) to mention but a few examples. Many of these
molecular targets are involved in multiple cellular processes and appear to be commonly responsive
to different compounds and thus, different bioactives or bioactive-containing products appear to exert
their anti-inflammatory effects by downregulating the expression of pro-inflammatory cytokines such
as TNF, IL1B and IL6, to reduce weight gain by altering key metabolic regulators like PRKAs (AMPK),
PPARs or UCPs or to exert antioxidant effects by the modulation of key targets such as HMOX1 or
GPX (extensive reviews on the regulation of genes by plant food bioactives in relation with chronic
disorders can be seen at [1–8]. It has been proposed that the molecular responses to the bioactive
compounds may be universal and present a high level of complexity given the large number of
different molecules that can be modulated in the different types of cells and tissues within the body [9].
The specific mechanisms by which the dietary bioactive compounds or their derived metabolites may
affect the different molecular targets have not yet been elucidated. Many of the molecular target
changes have been shown at the level of gene expression and thus, it has been postulated that the
effects of the bioactive compounds may be mediated by the induction or repression of gene expression
via direct molecular interaction (signaling pathways, transcription factors) or, most likely, by epigenetic
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Another crucial issue that remains unresolved is the verification in humans of the proposed
molecular responses to the intake of these compounds. An increasing number of human intervention
trials have attempted to explore the effects of the consumption of different bioactive compounds or
bioactive-containing foods or products on gene expression in different human tissues but, the results
are still very limited. Despite the guiding principles proposed by the MIQE guidelines [11] to improve
the general quality of gene expression biomedical research, many errors such as inappropriate study
design and sampling protocols and gene expression data analysis-related incorrectness continue to be
reported [12]. The validation of the involvement of specific gene targets and molecular mechanisms
in the response to specific bioactive compounds or metabolites poses an extra level of difficulty in
human dietary intervention studies that, at present, is far from being resolved. In this review, we have
Nutrients 2018, 10, 807 3 of 38
compiled a selection of human intervention trials in which the sample population was challenged with
a source of bioactive compound(s), i.e., diets, foods or food-derived products (extracts, drinks, oils)
and in which gene expression responses were investigated in different cells and tissue samples using
RT-qPCR, the gold standard for accurate and sensitive measurement of gene expression [13]. Our main
aims were to: (1) critically appraise the experimental design, methodology and gene expression
data analysis applied in these studies; and (2) re-examine and discuss the accumulated evidence
and relevance of the attained results. We herein reinforce the urge to follow general normalized
procedures to improve the quality of future nutrigenomic studies so that we can collect most reliable
gene expression responses to food bioactive compounds in humans and provide better evidence of the
molecular targets and mechanisms underlying the beneficial effects of these compounds.
2. Literature Searching, Studies Selection and Data Extraction
This review has collected human clinical trials in which the test group of volunteers was
administered with different dietary sources of bioactive compounds and where potential gene
expression changes were investigated in human cells or tissues using RT-qPCR in response to the
intervention. A search of the literature was undertaken using the PubMed database (last date assessed
February 2018). Several key words were used in combination: (human OR humans OR patient OR
patients OR volunteer* OR participant* OR subject* OR male OR males OR female OR females OR
men OR women) AND (gene regulation OR nutrigenomic* OR gene OR genes OR gene expression OR
transcription OR transcriptomic* OR mRNA OR messenger RNA OR RT-PCR OR real-time PCR OR
PCR-arrays) AND (plant bioactive* OR polyphenol* OR phenolic* OR flavonoid* OR carotenoid* OR
phytosterol* OR glucosinolate* OR fatty acids).
Human trials performing only microarray analyses for gene expression changes in response to
dietary bioactive compounds were not specifically searched for and, therefore, not included in this
review because of the broad diversity of analytical strategies, the complexity and large differences
in the data reporting, and the still requested validation of the results by RT-qPCR. This type of
studies deserves a complete separate revision. After we excluded some manuscripts reporting
only microarray results, we revised and compiled information from 75 human intervention trials
published between 1994 and 2018 (supplementary Table S1) [4,14–87]. Data extraction was conducted
by two independent reviewers (BP and MTGC) and distributed in Supplementary Tables S1–S3.
We classified the trials by intervention type and recorded the type of participants and trial design;
involved groups (control, treatment); dose and duration; and associated bioavailability studies
(Supplementary Table S1). We then assessed the reporting of several critical methodological details:
description, preparation and characterization of the biological samples; experimental protocols
applied for RNA isolation and characterization, and the selection of the reference gene(s) for data
normalization (Supplementary Table S2). We finally recorded the gene expression changes reported in
the manuscripts as potentially attributed to the interventions, the type of comparisons and sample
size for each group compared, as well as the data analysis and presentation. We additionally searched
for information about the potential association of the gene expression results with the presence of
bioactive compounds and/or derived metabolites detected in the body after the intervention and/or
with potential confirmatory changes at the protein level (Supplementary Table S3).
3. Summary of the Experimental Designs of the Intervention Trials Examined in this Review
Randomized controlled trials (RCTs) constitute one of the most powerful tools of research to
evaluate the effectiveness of intervention with a drug or a dietary compound such as bioactive
compounds on human health [88]. Of the studies included in this review (Supplementary Table S1) a
considerable proportion (76%) was randomized with ~60% designed in parallel groups and ~39% in
crossover. About 65% of these randomized studies were also blinded, most commonly (84%) double
blinded, indicating that a good proportion of the trials follow an appropriate design. A few parallel or
crossover studies did not report randomization and/or blinding. Regarding the sex of the participants,
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59% of the studies were conducted in mixed cohorts of men and women, 33% in groups of men and
only 8% in women. As for the health status, nearly 60% of the studies were carried out in healthy
volunteers including some healthy obese people, smokers and sportive individuals. Among the disease
groups, gene expression studies were carried out in patients with various disorders such as metabolic
syndrome (MetS), diabetes, hypertension, obesity, risk of cardiovascular disease (CVD), diverse types
of cancer (oral, colon, prostate, leukemia) and various other inflammatory diseases (chronic gastritis,
photo-dermatosis, sickle cell disease, Friedrich ataxia, non-alcoholic fatty liver disease, cystic fibrosis).
We have collected a total of 75 intervention studies looking at the effects on gene expression of the
intake of a variety of sources of bioactive compounds, from complex mixtures such as mix meals and
diets (fruit + vegetable diets, Mediterranean diets), foods and derived food products (broccoli, oils,
nuts, beverages, onions, fermented papaya, propolis), and extracts and supplements (grape, berry and
pomegranate extracts, plant extracts, oil derived extracts and compounds, mixed supplements),
to single compounds such as β-carotene (β-car), eicosapentaenoic acid (EPA), docosahexaenoic acid
(DHA), resveratrol (Res), quercetin (Quer), flavopiridol, genistein, epigallocatechin gallate (EGCG),
and curcumin (Cur). The duration of the interventions ranged from a few days up to one year but
most studies were carried out in periods between one and 3–4 months. Approximately 15% of the
studies were classified as acute or postprandial since gene expression was measured within 3–24 h of
the intake. The doses of the test compounds/products were very variable and fluctuated between a
few mg to g quantities. For example, the doses employed with single bioactive compounds varied
between 30 mg of β-car [71], Quer [79], or genistein [83], up to nearly 3 g of EPA/DHA [72] or Res [76]
and even up to 12 g of Cur [87]. Comparisons between several doses were also investigated in several
studies (n = 19) and in 3 studies the exact daily dose of the treatment was not reported.
One of the most critical points in a clinical trial design is the use of appropriate control groups
and one of the best approaches should be the use of a matched placebo in which the control group
would consume an almost identical test product containing all the constituents except for the bioactive
ingredient [89]. The selection of a suitable control group is particularly complicated in trials with
dietary interventions as evidenced by the variety of comparative strategies applied in the different
studies included in this review. There were a considerable number of single-arm studies that did
not include comparison to a control group and the changes in gene expression were only reported
between after (post-) and before (pre-) intervention. Other trials estimated gene expression differences:
(i) between low vs. high doses of the test bioactive compound(s), as in several studies looking at the
effects in gene expression of the bioactive compounds present in the olive oil [27,28,30,31,34,35] or those
present in broccoli sprouts [21,26]; (ii) between different diets [18,19] or food products [22,32,33,55];
and (iii) comparison to a placebo group [15,49–51] not always well described.
Around 50% of the trials included the study of the appearance and/or changes in urine,
plasma and/or in some tissues of the levels of different compounds and metabolites that were
potentially derived from the intake of the test product, i.e., bioavailability studies. For example,
the intake of mix fruit and vegetable was found to be associated with changes in the levels of
carotenoids in plasma and of flavonoids in urine [15–17], the intake of broccoli with increases of
sulphoraphane metabolites in urine and plasma [21,22,25], the intake of olive oil products with changes
in tyrosol (Tyr) and derived metabolites (hydroxytyrosol, HTyr) in urine and plasma [28,30,31,34,35],
or the presence of urolithins in prostate [37] and colon [4] tissues with the intake of walnuts and
pomegranate. Some of the trials carried out with single compounds also reported the appearance of
β-car [71], EPA/DHA [72], Res [73,74,76,77], Quer [80,81] or EGCG [85]. Of note, a few trials reported
a high interindividual variability in the presence of the bioactive compounds and/or metabolites in
the biological samples examined [4,37,76].
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4. Overview of Some Critical Issues Related to the RT-qPCR Experimental Protocols Used in the
Intervention Trials
RT-qPCR remains a most sensitive and reliable technique that can specifically measure small to
moderate changes in mRNA levels in cells and tissues in response to environmental challenges [13]
such as those promoted by dietary supplementation with bioactive compounds and/or foods and food
products enriched in these compounds. Supplementary Table S2 collects information about some of
the most critical points relative to the RT-qPCR experimental protocols form all the human intervention
studies gathered in this review, i.e., type of samples (cells or tissues) and preparation, RNA extraction
protocols and quantity/quality assessment as well as the house keeping gene(s) used as a reference for
data normalization.
4.1. Sample Characterization and Handling
The majority of the intervention studies included in this review used RNA extracted from whole
blood (10 studies) or from blood isolated immune cells (40 studies), principally from peripheral
blood mononuclear cells (55%), as the target tissues in which to measure gene expression changes
that might be attributed to the intervention with the test products containing bioactive compounds.
Also, isolated lymphocytes were the target tissue in seven studies [14,38,42–44,60,79], and monocytes,
polymorphonuclear granulocytes and neutrophils were used in one or two studies [23,45,60,81]. A total
of 10 studies reported gene expression changes in tissue samples from the gastrointestinal tract (oral,
stomach, small intestine and colon samples) [4,21,47,48,52,54,61,66,71,86]. Other additional internal
tissue samples used in humans were biopsies from prostate [29,37,83], adipose tissue [36,73,74,85],
skeletal muscle tissue [73–75,80,84] and skin samples [46,59,68,69]. One study looked at gene
expression changes in cells present in nasal lavage [22]. In general, and despite the fact that all
these blood cells and tissue samples are heterogeneous and constituted by different types of cells,
most of the studies examined here did not report a complete blood count and blood cell proportions
or some description of the cell types and composition present in any of the investigated tissues.
Only one study, reported the proportion of immune cells forming the isolated mononuclear cell samples
showing moderate interindividual variability in the cell composition: lymphocytes (84.4 ± 2.9%),
monocytes (13.0± 3.2%) and granulocytes (2.2± 1.4%) [51]. A few other studies reported mononuclear
cells purity (>95%) [58], isolated blast cells enrichment (>70%) [82], or neutrophils enrichment and
viability (>90% cells, 90% viable) [45]. In the biopsies, classification between cancer and non-cancerous
tissue samples was indicated to be carried out by specialized pathologists but no further description
of the cell composition within the samples was included [4,37]. Only one study used laser capture
microdissection for tissue sampling attaining a specific number of cells (10,000) from benign and from
normal tissues [83].
Sample handling and preparation protocols also contribute to the experimental variability and
thus, it is important to report in as much detail as possible how the samples were obtained and
processed until use [11]. The revision of this part of the experimental protocol in all the selected
articles evidenced a general poor or limited description of the procedure used to obtain the samples
as well as about the processing time, the sample storage conditions and the time elapsed until RNA
extraction. There is a broad variation in the sampling procedures used or the information reported
with a considerable number of studies including few details. For example, for the gene expression
studies carried out in whole blood, only half of them specifically reported the collection of fasting
blood samples. Also, only six of these studies applied a specific commercial kit for direct RNA isolation
from blood whereas the rest of the studies did not provide any information about the protocol used.
In those cases where the storage was reported, the most common way of long term sample storing
was at −80 ◦C (as shown in ~40% of the studies). However, the time elapsed before storage was not
reported in many of the studies and, in those where it was indicated, it varied from quick-freezing in
liquid N2 to maintenance and/or transport at room/low temperature for several hours before freezing.
The preservation solution varied between studies (RNAlater or lysis buffer were most commonly
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used, but other buffers, DEPC-treated solutions, or even specific cell culture medium were also used).
Further, and importantly, there was no reporting of the storage time period prior to the RNA extraction
except for one study that indicated to have done gene expression analyses within one month of
storage [61].
4.2. RNA Extraction Protocols, Quantity and Quality
RNA extraction, quantitation and integrity inspection are also critical steps that can influence
the gene expression changes. The use of different RNA extraction protocols may account for some of
the differences in gene expression results and various factors can affect the final quantity and quality
of the isolated RNA (i.e., degradation by ubiquitous RNases, co-extraction of inhibitors, presence of
contaminant DNA and/or protein) potentially compromising the results of the RT-qPCR analysis [12].
This is especially critical if we want to compare results from different studies. In this review, most of
the studies indicated to have isolated the RNA using one of the many different commercially available
extraction kits including mostly those based on affinity columns or those using the Trizol reagent and
liquid-liquid extraction. Nevertheless, about 17% of the studies did not describe clearly the protocol
used. In addition, of all the studies included, only 12 studies (16%) specified to have applied a DNase
treatment in the procedure to remove contaminating genomic DNA.
Reliable analysis of changes in the mRNA levels requires that the extracted RNA is of high quality
and that both the quantity and integrity is accurately determined [90]. This is especially relevant in
human clinical studies with usually limited and unique tissue samples, however, not many publications
report RNA yield and/or quality values [12]. In this review, most of the selected studies that indicated
to have measured the quantity of extracted RNA, reported to have done so by spectrophotometry
(Abs 260 nm) using the NanoDrop system in many cases. Only in one study they used the Ribogreen
method [44]. Nevertheless, none of the studies presented information about the RNA yield obtained
from the specific cells or tissues analyzed except for one study where they indicated an average RNA
yield of 0.3–1.0 µg extracted from nasal lavage samples [22].
Of the 75 clinical studies included in this review, we found that 66 publications (88%) did not
report any quality score of the RNA samples used in the gene expression studies even though,
a considerable number of these studies reported to have assessed the quality of the RNA, either by
spectrophotometry determination of the Abs260/280 (mostly using the NanoDrop system) or by agarose
gel and examination of the 18S and 28S bands (often using the Bioanalyzer capillary chips). Of those
studies that included information about the RNA quality, two of them only mentioned that some of
the samples had low quality [15,82] and four studies reported the quality of the ARN based solely on
the Abs260/280 with values between 1.8 and 2.1 [37,67,74,75]. Two studies reported the RNA integrity
number (RIN) values of their samples, RIN > 8.0 [64] and RIN = 6–9 [54], respectively, and only two
other studies combined Abs260/280 and RIN values [4,51] to prove the quality of their RNA samples.
4.3. Reference Genes
The selection of genes stably expressed to be used as endogenous or reference genes remains
the most common method for mRNA data normalization and a critical issue in RT-qPCR studies,
especially when working with heterogeneous tissue samples. The incorrect use of reference genes
can have a profound impact on the results of the study [91]. Table 1 displays the list of reference
genes, with the most updated nomenclature available from GeneCards [92], used in the intervention
studies included in this review. The majority of these studies used a single gene as a reference
with GAPDH being the most commonly one applied, followed by ACTB and 18S rRNA. The rest of
the studies applied other common but yet less frequently used genes such as B2M, HPRT1, GUSB,
or ribosomal proteins. There were also two studies in which normalization was carried out using
the gene AW109 [62], an RNA competitor [93], and single stranded DNA (ssDNA) [75], respectively,
as references. As for the type of samples in which these genes were used for normalization, the three
top reference genes, GAPDH, ACTB and 18S rRNA, were indistinctively used in a wide range of
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cell types and tissue samples, i.e., whole blood, mononuclear cells, other various isolated immune
circulating cells (lymphocytes, monocytes, neutrophils), gastrointestinal biopsies, prostate biopsies,
skeletal muscle, adipose tissue and skin. On the other hand, in mononuclear cells (the primary type of
cells used in the gene expression human studies) most of the listed genes (GAPDH, ACTB, 18SrRNA,
HPRT1, B2M, UBC, PPIA, HMBS, YWHAZ, RPL13A, RPLP0) were used as reference genes.
Table 1. List of reference genes reported in the human intervention studies included in this review.
Gene Symbol n Studies 1 Cell/Tissue Samples in Which the Gene
Has Been Used as a Reference Gene




1 tested, but not used [63]
Blood, white blood cells, mononuclear cells,
lymphocytes, neutrophils, gastric antrum,
colon cancer and colon normal tissue,
prostate hyperplasia and prostate cancer




1 tested, but not used [53]
Blood, white blood cells, leukemic blasts,
lymphocytes, CD14+ monocytes, colon
cancer and colon normal tissue, skeletal
muscle tissue, skin tissue
18S rRNA
11 [15,17,21,22,24,56,59,61,80,85,87]
1 considered, but not used [66]
White blood cells, mononuclear cells,
skeletal muscle tissue, buccal swabs, gastric
mucosa, adipose tissue, nasal cells,
epidermis blister, buttock skin
Other genes less commonly used as reference genes
B2M 6 [18,40,70,71,74,82]
Blood, mononuclear cells, leukemic blasts,
colon tissue, skeletal muscle, adipose tissue
HPRT1 3 [18,38,40], 2 tested, but not used [4,72]
1 considered, but not used [66]
Blood, lymphocytes
GUSB 2 [29,52], 1 tested, but not used [4] Oral mucosa, prostate tissue
RPLP0 3 [40,60,82], 1 tested, but not used [63]
Blood, leukemic blasts, lymphocytes,
neutrophils
RPL13A 1 [27] Mononuclear cells
RPL32 1 [36] Adipose tissue
HMBS 2 [45,47] Neutrophils, colon mucosa
ATP5O 1 [66] Duodenal biopsies
DUSP1 1 [54] Oral biopsies
ALAS1 1 [83] Prostate cancer and normal tissue
YWHAZ 1 [38] Lymphocytes
UBC 1 [58] Mononuclear cells
PPIA 1 [58] Mononuclear cells
G6PD 2 [66,72]
Blood (tested but not used), duodenal tissue
(selected but not used)
Other reference molecules used
AW109 1 [62] Mononuclear cells
ssDNA 1 [75] Skeletal muscle
1 Number of studies that report to have used and/or tested the reference gene. Genes nomenclature
from GeneCards [92] (in alphabetical order): ACTB, actin beta; ALAS1, 5′-aminolevulinate synthase 1;
ATP5O, ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit; AW109, competitor RNA; B2M,
beta-2-microglobulin; DUSP1, dual specificity phosphatase 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
GUSB, glucuronidase beta; G6PD, glucose-6-phosphate dehydrogenase; HMBS, hydroxymethylbilane synthase
(alias: PBGD, porphobilinogen deaminase); HPRT1, hypoxanthine phosphoribosyltransferase 1; PPIA,
peptidylprolyl isomerase A; RPLP0, ribosomal protein lateral stalk subunit P0 (36B4 rRNA: encodes for RPLP0);
RPL13A, ribosomal protein L13A; RPL32, ribosomal protein L32; 18S rRNA, 18S ribosomal RNA; ssDNA,
single stranded DNA; UBC, ubiquitin C; YWHAZ, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein zeta.
Only a few studies indicated to have used the average value or the combination of various
reference genes (GAPDH, ACTB, HPRT1, B2M) [18,40], (GAPDH, ACTB) [64] and (ACTB, UBC,
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PPIA) [58] for the normalization process whereas others reported to have used separate reference genes
(RPLP0, ACTB, B2M) [82] and (GAPDH, HMBS) [45] for the analysis of expression changes of different
target genes within the same study. A total of seven studies did not clearly report the use of or the
specific reference gene employed in their analyses. Regarding the criteria employed to choose the
reference gene(s), very few studies indicated to have taken into consideration either information from
the literature [66], the RefGenes tool in the curated expression database Genevestigator [38] or to have
determined the stability of the genes using specific tools such as GeNorm or Normfinder [4,76].
4.4. Gene Expression Data Reporting
Supplementary Table S3 compiles information about the different genes that were investigated
in each of the trials included in this review. In general, and regarding the sample size, most gene
expression analyses were carried out using a small number of individuals per group (generally <25 and,
frequently, the control and treated groups were integrated by less than 10–15 individuals). Table S3
includes the list of genes that were found upregulated (↑, red color) or downregulated (↓ green color)
in response to each intervention. When available, we added the significance of the change (p-value)
and the specific comparison in which the change was detected. We also annotated those genes that
exhibited a not significant change and those that were reported not to be affected with the treatment.
This information specifically shows the variety of comparative strategies and presentation of results
(gene expression change) used in the different studies. Differential expression was reported for some
genes as: (i) the difference between after (post-) and before (pre-) intervention (↑HMOX1 in blood after
intervention with 150 g of broccoli [26]); (ii) the difference between the treated and the control group
only at the end of the intervention period (↑PPARA in blood in a group consuming EPA or DHA against
a control group, [72]). There were various other comparative approaches such as between different
doses of the bioactive compounds (↑PPARA in white blood cells when comparing olive oil with a
high level of polyphenols vs. olive oil with a moderate dose of polyphenols [31]), between different
diets (↓UCP2 in blood with tocopherol-enriched Mediterranean diet vs. a Western high-fat diet [19] or
between different food products (↑HMOX1 in cells from nasal lavage after intervention with 200 g of
broccoli sprouts vs. 200 g of alfalfa sprouts [22]).
For the estimation of the gene expression changes, the majority of the trials reviewed
here used relative expression quantification applying the Ct comparative method based on a
standard curve, normalized Ct values (using a reference gen) and the 2(−∆∆Ct) formula [94].
Nevertheless, the presentation of the results (expression changes) also varied a lot between the
studies. The changes in the genes were reported either as relative expression levels in the different
groups (occasionally as arbitrary units or as the number of copies of mRNA), as a change (typically
as FC or ratio but also as the % of change) or as a combination of both within the same report.
The final results were typically presented using a statistical approach to describe the central tendency
and the dispersion of the results but there was also a high variability in the estimators used in
each study. Around 65% of the studies used the mean value as an estimator of the average
changes but a few studies reported the median [4,14,43,51,66,76] or even the geometric mean of
the data [31]. Regarding the dispersion of the results, most studies indicated either the SEM (~35%)
or the SD (~29%) but some studies reported the confidence intervals [18,31,47,54,62,77,86] or the
quartiles/ranges [4,14,37,42,43,51,66,76,82]. Overall, there was a considerable lack of clarity in the
presentation of the results, many of which (~50%) were included only in figures not always well
described. In some studies it was not trivial to infer the evidence supporting the changes. Between 23%
and 24% of the studies failed to report or to correctly identify the measurement of the average change
or the data variability. Of note, a few studies reported the distribution of gene expression changes in
the sample population, e.g., % of individuals exhibiting downregulation, upregulation or no change
for a particular gene [4,82,86] whereas in some other studies, individual gene expression changes were
displayed [14,54,57].
Nutrients 2018, 10, 807 9 of 38
4.5. Gene Expression Results: Association with Bioavailability of Bioactive Compounds and/or with Protein
Confirmatory Studies
Of the trials collected in this review that reported the presence of certain compounds and
metabolites in the blood, urine and/or tissue samples (bioavailability), only a few (17 studies)
attempted to investigate the potential relationship between the gene expression changes detected
and the appearance and/or concentration of the specific compounds and/or metabolites. Only 5 of
those studies reported some positive or inverse correlations between the changes of the expression in
some genes and the levels of some metabolites. For instance, the downregulation of the expression of
IFNG, OLR1 or ICAM1 and the upregulation of ABCA1 in peripheral blood cells in association with
the increase of Tyr and/or HTyr metabolites in urine or plasma following the intake of olive oil rich
in polyphenols [28,30,31]. With regards to the validation of the gene expression changes by further
testing the levels of the corresponding proteins and/or protein activity, only 27 studies (36% of total)
made an attempt to substantiate gene changes with protein changes. In those, ~50% of the examined
gene changes resulted in some confirmatory protein changes, e.g., the downregulation of TNF in blood
and the reduction of the plasma levels of TNF following the intake of a grape seed extract [49] or,
the upregulation in mononuclear cells of LDLR and the increase in the levels of LDLR in monocytes
and T-lymphocytes after the intake of mix plant stanol esters [62].
5. Gene Expression Changes in Human Cells and Tissues in Response to Food Bioactive
Compounds: Overview of the Accumulated Evidence
5.1. Gene Expression Changes Specifically Reported in Blood Isolated Immune Cells in Response to Different
Sources of Bioactive Compounds
Table 2 collects the genes reported to be significantly (p-value < 0.05) up- or downregulated in
blood isolated immune cells after intervention with dietary foods or products containing bioactive
compounds. The table indicates the type of cells where the study was carried out, the comparison in
which the changes were detected and the potential bioactive compounds involved in the response.
Most of the studies were carried out in peripheral blood mononuclear cells but there were some
studies looking at isolated lymphocytes [14,34,42,43,79], neutrophils [45,60] or granulocytes [23].
Most trials were carried out with foods or products containing mixed bioactive compounds and only
a few studies investigated the effects of isolated compounds, e.g., Quer [79,80] or EPA/DHA [65,67].
The table also indicates the biological processes and health effects investigated in each study in relation
with the response to the intervention and to which the changing genes might be associated with,
i.e., metabolism of lipids and carbohydrates and associated disorders (atherosclerosis, high blood
pressure), regulation of the inflammatory status, and oxidative stress and antioxidant responses.
The messages associated with the different interventions and with the changing genes were messages
of improvement or beneficial effects. Some of the genes most commonly investigated in relation
with these responses and that might be considered as targets responsive to bioactive compounds
included well known transcriptional factors, cytokines, key metabolic regulators and antioxidant
genes. For instance, some members of the PPAR family (PPARG) were upregulated in circulating
blood immune cells in response to the intake of mixed bioactive polyphenols and fatty acids [31,67,70].
Also, some cytokines (TNF) and interleukins (IL1β, IL6) were found to be downregulated in this type
of cells following intervention with different oils [27,67], fruit extracts [51] or nuts [38]. Regarding the
transcription factors, NFKB and EGR1 were downregulated in these cells after the intake of mixed
omega-3 [65] or mixed olive oil bioactive compounds [27,64] whereas NFE2L2 was found increased in
response to the mixed compounds present in sunflower oil [32] and in coffee [42,43] but downregulated
in response to the intake of a berry extract rich in anthocyanins [53]. Several genes related with the
antioxidant status regulation (SODs, CAT, GPX1) also exhibited up- or downregulation in the immune
cells with different interventions [32,42,45,60].
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Table 2. Overview of the significant gene expression changes reported in peripheral blood isolated immune cells in response to different interventions with various
diets, foods, or derived products containing bioactive compounds (p-value < 0.05).
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protein 15; CALR, calreticulin (alias: CRT); CAT, catalase; CCL2, C-C motif chemokine ligand 2 (alias: MCP-1, monocyte chemotactic protein 1); CCL3, C-C motif chemokine ligand 3; CD36,
CD36 molecule; CD40LG, CD40 ligand; CPT1A, carnitine palmitoyltransferase 1A; CRAT, carnitine O-acetyltransferase; CXCL8, C-X-C motif chemokine ligand 8 (alias: IL8); CXCR2,
C-X-C motif chemokine receptor 2 (alias: IL8RA); CYBA, cytochrome B-245 alpha chain (alias: P22-Phox); CYBB, cytochrome B-245 beta chain (alias: NOX2, GP91-Phox); EGR1, early growth
response 1; GPX1, glutathione peroxidase 1; GSTP1, glutathione S-transferase Pi 1; GSR, glutathione-disulfide reductase (alias: GRD1); HMOX1, heme oxygenase 1 (alias:HO-1); HSPA5,
heat shock protein family A (Hsp70) member 5 (alias: BIP); ID3, inhibitor of DNA binding 3, HLH protein; IFNG, interferon gamma; IL1B, interleukin 1 beta; IL6, interleukin 6; IL7R,
interleukin 7 receptor; IL10, interleukin 10; IL23A, interleukin 23 subunit alpha; IRS1, insulin receptor substrate 1; LDLR, low density lipoprotein receptor; LRRFIP1, LRR binding FLII
interacting protein 1; MAPK8, mitogen-activated protein kinase 8 (alias: JKN1); MED1, mediator complex subunit 1 (alias: PPARBP); NFE2L2, nuclear factor, erythroid 2 like 2 (alias:
NRF2); NQO1, NAD(P)H quinone dehydrogenase 1; NOS2, nitric oxide synthase 2 (alias: iNOS); NR1H2, nuclear receptor subfamily 1 group H member 2; OGG1, 8-oxoguanine DNA
glycosylase; OLR1, oxidized low density lipoprotein receptor 1; POLK, DNA polymerase kappa; PPARA, peroxisome proliferator activated receptor alpha; PPARD, peroxisome proliferator
activated receptor delta; PPARG, peroxisome proliferator activated receptor gamma; PTGS1, prostaglandin-endoperoxide synthase 1 (alias: COX1); PTGS2, prostaglandin-endoperoxide
synthase 2 (alias: COX2); PTPN1, protein tyrosine phosphatase, non-receptor type 1 (alias: PTP1B); RETN, resistin; SCARB1, scavenger receptor class B member 1 (alias: SRB1); SLC2A4,
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X-box binding protein 1. Orange color: upregulated genes; green color: downregulated genes.
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5.2. Accumulated Evidence for Specific Gene Targets in Response to Different Sources of Bioactive Compounds
We specifically looked at all the changes reported in different cells and tissues for some genes
that might be considered targets responsive to bioactive compounds and that are associated with
inflammation (TNF) (Supplementary Table S4), energy metabolism (PPARs) (Supplementary Table S5),
and antioxidant effects (GPXs) (Supplementary Table S6). As already stated, data reporting was
variable among the studies and the quality of the results was generally poor. Where possible and
using the information available from the articles we estimated the coefficient of variation (CV) of the
reported gene expression changes. Overall, between 40% and 60% of the studies reported a lack of
effect of the intervention on the selected genes.
Main details and results from those other studies reporting significant outcomes for TNF,
PPARs and GPXs expression changes are gathered in Table 3. Based on these results, it would appear
that the intake of different mix bioactive compounds could be associated with the downregulation
of TNF and the upregulation of some PPARS (PPARA, PPARG) and GPXs (GPX1) genes in blood
and/or in isolated blood immune cells. There were, however, some opposed significant results
such as the upregulation exhibited by TNF expression levels in blood in response to EPA/DHA [72].
Also, different members of the same family of genes may react differently as it was the case of the GPX
genes in response to the intake of hazelnuts [40]. Regarding the effect size (gene expression changes)
and, for comparative purposes, we estimated and converted all the results into FC-values and % of
change. We observed a large variation in the changes reported ranging from very small FC-values,
e.g., +1.06 (6%) for PPARG in mononuclear cells [67] or +1.07 (7%) for TNF in blood [72] to rather
high changes, i.e., FC > +2.5 (>150%) such as those reported for some members of the PPARs and
GPXs families [18,31,70]. As for the variability in these gene expression responses, in those studies
for which we were able to estimate the CV, these CV values were high and variable. In some cases,
the % of change attributed to the intervention was in the range of the estimated CV, e.g., the 11%
reduction of TNF by fish oil EPA + DHA with an estimated variability of 10.5–18.0% [67]. In other
studies, the CV was well above the % of change attributed to the intervention, e.g., a 100% increase
in PPARA attributed to mix olive oil compounds with estimated CV values > 100% [31]. In addition,
none of these studies reported the potential association between those gene expression changes and
the presence or changes in the quantities of specific compounds or derived metabolites in the samples
and, there was little or none evidence supporting the regulation of the corresponding encoded proteins.
Overall, the level of evidence supporting the specific described gene changes as potential mechanisms
of response to the intake of the bioactive compounds present in the test food products investigated
remains very low.
5.3. Summary of the Effects on Gene Expression of Specific Food Products Containing Bioactive Compounds
Table 4 gathers the reported changes on gene expression following the consumption of three of
the most investigated plant derived foods and products containing different families of bioactives,
i.e., olive oil and extracts rich in polyphenols, mostly focused on Tyr and HTyr [27,28,30,31,34–36,63,64];
broccoli sprouts and derived products rich in sulphoraphane glucosinolates (SFGluc) [21–26];
and grape extracts containing polyphenols, mainly with a focus on Res [48–51,73–78]. Most of these
gene expression changes were investigated in blood or peripheral blood immune cells except for a few
studies conducted in adipose and/or skeletal tissue, and in samples from the gastrointestinal tract.
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Table 3. Overview of the significant expression changes reported for specific gene targets in different cells and tissue samples following intervention with diet, foods,
or derived products containing bioactive compounds. Analysis of the evidence supporting the changes and, the potentiality of these changes as a mechanism of action
underlying the beneficial effects attributed to these products and bioactive compounds (p- value < 0.05).
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1 White blood cells or Leukocytes: mononuclear cells agranulocytes (lymphocytes and monocytes) and polymorphonuclear granulocytes (neutrophils, eosinophils, basophils, mast cells).
Table abbreviations (in alphabetical order): CV, coefficient of variation; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FC, fold-change; L-carn, L-carnitine; LPS, lipopolysaccharide;
McD, MacDonald; Med, Mediterranean; NC, no change; post-, after treatment; pre-, baseline or before treatment; PUFA, polyunsaturated fatty acids; Res, resveratrol; Se, selenium; VitC,
vitamin C; VitE, vitamin E. Genes nomenclature from GeneCards [92] (in alphabetical order): GPX1-4, glutathione peroxidase 1-4; MED1, mediator complex subunit 1 (alias: PPARBP);
PPARA, peroxisome proliferator activated receptor alpha; PPARD, peroxisome proliferator activated receptor delta; PPARG, peroxisome proliferator activated receptor gamma; TNF,
tumour necrosis factor (alias: TNFα). Orange color: upregulated genes; green color: downregulated genes.
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Table 4. Overview of the significant gene expression changes attributed to the intervention with specific foods or derived products containing bioactive compounds
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1 White blood cells or Leukocytes: mononuclear cells agranulocytes (lymphocytes and monocytes) and polymorphonuclear granulocytes (neutrophils, eosinophils, basophils,
mast cells). Table abbreviations (in alphabetical order): β-car, β-carotene; HTyr, hydroxytyrosol; LDL, low-density lipoprotein; Lut, lutein; Med, Mediterranean; NC, no change;
NR, not reported; NS, not significant; MUFA, monounsaturated fatty acids; PBMC, peripheral blood mononuclear cells; post-, after treatment; pre-, baseline or before treatment;
Res, resveratrol; SFGluc, sulphoraphane glucosinolates; Tyr, tyrosol; VitC, vitamin C. Genes nomenclature from GeneCards [92] (in alphabetical order): ABCA1, ATP binding
cassette subfamily A member 1; ABCG1, ATP binding cassette subfamily G member 1; ACE, angiotensin I converting enzyme; ADRB2, adrenoceptor beta 2; ADGRE1, adhesion G
protein-coupled receptor E1 (alias: EMR1); ALOX5AP, arachidonate 5-lipoxygenase activating protein; ARHGAP15, rho GTPase activating protein 15; CAT, catalase; CCL2, C-C motif
chemokine ligand 2 (alias: MCP-1, monocyte chemotactic protein 1); CCL3, C-C motif chemokine ligand 3; CCND1, cyclin D1; CD36, CD36 molecule; CD40LG, CD40 ligand;
CDKN1A, cyclin dependent kinase inhibitor 1A (alias: p21); CXCL8, C-X-C motif chemokine ligand 8 (alias: IL8); CXCR1, C-X-C motif chemokine receptor 1; CXCR2, C-X-C motif
chemokine receptor 2 (alias: IL8RA); CYBB, cytochrome B-245 beta chain (alias: NOX2, GP91-Phox); ECE2, endothelin converting enzyme 2; EGR1, early growth response 1;
EMR1, FXN, frataxin, Friedreich ataxia protein; GCLC, glutamate-cysteine ligase catalytic subunit (alias: γGCL); GPX1, glutathione peroxidase 1; GPX4, glutathione peroxidase 4;
GSTA1, glutathione S-transferase alpha 1; GSTA4, glutathione S-transferase alpha 4; GSTK1, glutathione S-transferase kappa 1; GSTM1, glutathione S-transferase Mu 1; GSTM2,
glutathione S-transferase Mu 2; GSTM3, glutathione S-transferase Mu 3; GSTM4, glutathione S-transferase Mu 4; GSTM5, glutathione S-transferase Mu 5; GSTO1, glutathione S-transferase
omega 1; GSTO2, glutathione S-transferase omega 2; GSTP1, glutathione S-transferase Pi 1; GSR, glutathione-disulfide reductase (alias: GRD1); HBG1, hemoglobin subunit gamma 1;
HMOX1, heme oxygenase 1 (alias:HO-1); HNMT, histamine N-methyltransferase; ICAM1, intercellular adhesion molecule 1; ID3, inhibitor of DNA binding 3, HLH protein; IFNG,
interferon gamma; IL1B, interleukin 1 beta; IL6, interleukin 6; IL7R, interleukin 7 receptor; IL8, interleukin 8; IL10, interleukin 10; IL23A, interleukin 23 subunit alpha; INMT, indolethylamine
N-methyltransferase; JUN, jun proto-oncogene, AP-1 transcription factor subunit; LPL, lipoprotein lipase; LRRFIP1, LRR binding FLII interacting protein 1; MED1, mediator complex
subunit 1 (alias: PPARBP); MGST1,microsomal glutathione S-transferase 1; MGST2, microsomal glutathione S-transferase 2; MGST3, microsomal glutathione S-transferase 3; MPO,
myeloperoxidase; MYC, MYC proto-oncogene, BHLH transcription factor; NAMPT, nicotinamide phosphoribosyltransferase; NFKB1, nuclear factor kappa B subunit 1; NFKBIA,
NFKB inhibitor alpha; NQO1, NAD(P)H quinone dehydrogenase 1; NQO2, N-ribosyldihydronicotinamide: quinone reductase 2; NOS2, nitric oxide synthase 2 (alias: iNOS); NR1H2,
nuclear receptor subfamily 1 group H member 2; NUDT1, nudix hydrolase 1; OGG1, 8-oxoguanine DNA glycosylase; OLR1, oxidized low density lipoprotein receptor 1; POLK,
DNA polymerase kappa; PPARA, peroxisome proliferator activated receptor alpha; PPARD, peroxisome proliferator activated receptor delta; PPARG, peroxisome proliferator activated
receptor gamma; PPARGC1A, PPARG coactivator 1 alpha (alias: PGC1α); PTGS1, prostaglandin-endoperoxide synthase 1 (alias: COX1); PTGS2, prostaglandin-endoperoxide synthase 2
(alias: COX2); PTPN1, protein tyrosine phosphatase, non-receptor type 1 (alias: PTP1B); SCARB1, scavenger receptor class B member 1 (alias: SRB1); SERPINE1, Serpin Family E Member 1;
SIRT1, sirtuin 1; SLC2A4, solute carrier family 2 member 4 (alias: GLUT4); SOD1, superoxide dismutase 1 (alias: Cu/ZnSOD); SOD2, superoxide dismutase 2 (alias: MnSOD); TNF,
tumor necrosis factor (alias: TNFα); TNFSF10, TNF Superfamily Member 10; TXNRD1, thioredoxin reductase 1 (alias: TR1); UCP3, uncoupling protein 3; VCAM1, vascular cell adhesion
molecule 1; VEGFB, vascular endothelial growth factor B. Orange color: upregulated genes; green color: downregulated genes.
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A total of eight clinical trials that investigated the effects of the consumption of olive oil products
containing bioactive compounds (polyphenols) were included in this review. These studies focused on
the potential benefits of olive oil bioactives on energy metabolism, such as the regulation of the levels
of cholesterol [31,34], and on inflammatory related processes [27,30,64] as well as in the concurrent
regulation of the expression levels of specific genes related with these processes. The accumulated
evidence to support any of these genes as specific gene targets responsive to the intake of the
olive bioactives is still very limited although some of those genes display preliminary consistent
changes following the consumption of these products. For example, the gene ADRB2 was found to be
downregulated in mononuclear cells in three separate trials comparing the intake of olive oil containing
high vs. low doses of polyphenols [28,30,35]. Also, the transcription factor EGR1 which regulates
the transcription of numerous inflammatory related interleukins and cytokines [95], or the IL7R were
found downregulated in mononuclear cells in response to high-polyphenol olive oil and olive leaf
extract [27,28,30,64] supporting the anti-inflammatory effects attributed to these products. On the
other hand, the changes in the expression levels reported for other targets such as the chemokine
CCL2 were found to be reduced in mononuclear cells following 21 days of intervention with olive oil
polyphenols [30] as opposed to the induction reported in adipose tissue after 4 h of the intake of mix
olive oil bioactive compounds or the lack of effect detected in the same adipose tissue after 28 days
consuming the olive oil bioactive compounds [36]. PTGS2 (also designated as COX2 and critically
involved in the anti-inflammatory response) was found downregulated following intervention with
olive leaf polyphenols in mononuclear cells [64] but no significant change was detected in studies
conducted with olive oil polyphenols [27,31]. Regarding the specific bioactive compounds present in
the olive products, Tyr and derived metabolites (HTyr) have been investigated and reported as some
of the molecules potentially responsible for some of the gene expression effects observed in humans.
The upregulation of the membrane transporter ABCA1 has been related with the increase of the levels
of HTyr in plasma [31], or the downregulation of IFNG or OLR1 have been associated with the increase
of Tyr in urine [28,30].
Among the six intervention studies conducted with broccoli, the richest source of SFGluc, five trials
examined and reported the effects of this type of product in the expression of HMOX1. The results were
diverse with three studies giving significant evidence of the upregulation of this gene in blood [26],
in polymorphonuclear granulocytes [23], and in nasal lavage cells [22] whereas in the remaining two
studies, no change was detected in blood [25] or in mononuclear cells [24]. In all these intervention
trials, the main bioactive compound to which the effects might be potentially attributed to was the
SFGluc but, we found no evidence of the presence of SFGluc metabolites in the biological samples in
association with the specific gene responses. The overall accumulated evidence in humans of the gene
regulatory effects of SFGluc from broccoli remains limited.
The last group of bioactive-containing products gathered in Table 4 refers to studies conducted
with grape derived powders and extracts, to which anti-inflammatory, antioxidant and metabolic
benefits have also been attributed to. Some of the gene expression changes reported in humans after
intervention with these grape extracts shows downregulation effects in various interleukins and in
the multifunctional pro-inflammatory cytokine TNF [49,51]. In this latter study, the downregulation
of TNF has been associated with the presence of Res in the grape extract [51]. Grape products are
characterized by containing mix flavonoids, but it has received special attention for the presence of
Res, a widely investigated stilbenoid with many reported beneficial effects [96]. We have also gathered
in Table 4 several human trials in which the test product was the single compound Res. None of these
studies reported significant gene expression changes except for the downregulation of the glucose
transporter SLC2A4 in muscle tissue [74]. Of note, two studies reported the absence of effect on TNF in
skeletal muscle [75] and in adipose tissue [74]. Equally, two other studies reported the lack of effect on
the expression levels of the deacetylase SIRT1 [73,78], a well-established target of Res in pre-clinical
models [97].
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6. General Discussion
In this review, we have thoroughly examined 75 human clinical intervention studies published in
the past 20 years that investigated the health benefits of the intake of different bioactive compounds or
of foods or food products containing these compounds, and that included the study of the changes
promoted in specific gene targets in different cells and tissues using RT-qPCR. In general, there was
a poor quality in the design and description of the experimental protocols as well as in the analysis
and reporting of the gene expression changes posing doubts about the consistency and validity of the
published results. A similar scenario was illustrated for biomedical research [12] reinforcing the need
to apply the MIQE guidelines and well-established recommendations for RT-qPCR analyses [11,13] to
enhance the quality of future gene expression studies. We have compiled in Table 5 some of the most
critical experimental inaccuracies found in the human intervention studies reviewed here, in parallel
with some general recommendations that should be necessarily implemented in order to produce
more reliable gene expression results that could be truly attributed to the intake of dietary bioactive
compounds. On the basis of this Table, we suggest the feasibility of establishing a quality score
system that would define the validity and sufficiency of the human trials investigating gene expression
responses to intervention with dietary bioactive compounds, with a maximum score for those studies
implementing all the points proposed here, i.e., best study design, good sample population description
(even at individuals levels), good placebo-control and intervention groups that allow for the attribution
of the effects to the intake of specific compound(s), thorough application of the MIQE guidelines for
the RT-qPCR analyses, good comparative strategy and clarity of results presentation, assessment of
interindividual variability, parallel bioavailability studies that allow for potential association between
gene expression changes and the presence of specific compound(s) and/or derived metabolite(s) in the
analyzed biological samples, and last, but not least, potential confirmation of the gene changes at the
level of protein amounts and/or activity.
In spite of the limitations of the studies carried out so far, we have put together and revised the
accumulated evidence for some specific target genes commonly investigated in different samples,
especially in circulating immune cells, in response to different sources of bioactive compounds.
Blood isolated immune cells, and in particular, mononuclear cells (lymphocytes and monocytes)
have been used as surrogate cells in human gene expression studies since they are easy to obtain,
are considered to reflect the metabolic and immune processes that may occur in other tissues, e.g., liver,
adipose or skeletal muscle, but also, because of their own role in inflammation, obesity and other
cardiometabolic disorders. Nevertheless, not many genes have been yet confirmed as responsive
molecular candidates in relation with the effect of bioactive compounds against these diseases [98].
With regards of the studies carried out in blood isolated immune cells and included in this review,
very few genes have been repeatedly shown to be significantly regulated after the intake of several
foods and food products containing diverse bioactive compounds (Table 2). For instance, PPARG,
a member of the subfamily of nuclear hormone receptors PPARs that regulate the expression of many
genes, has been found commonly upregulated in blood immune cells following intervention with
mixed olive oil polyphenols [31], with a mixture of polyphenols, fatty acids and vitamins [70] or with
mixed EPA + DHA [67]. PPARG was originally described as a key regulator of lipid metabolism in
the adipocytes but it is also expressed in most immune cells where it attenuates the expression of
pro-inflammatory genes such as IL1β, TNF or IFNG and thus, the activation of PPARG constitutes also
an important anti-inflammatory strategy [99]. In the previous studies, the intake of those bioactive
compounds was associated with the reduction of triglycerides (TAGs) [31,67,70], oxLDL [31], and free
fatty acids (FFAs) [70] as well as with the increase of LDL- and HDL-cholesterol [67] giving some
evidence of regulatory effects in the lipid metabolism.
Nutrients 2018, 10, 807 23 of 38
Table 5. General recommendations to further enhance the quality and relevance of future intervention trials looking at the effects on gene expression of dietary
bioactive compounds in humans.
Specific critical issues related to the human gene expression studies
revised in this article that need improvement
Strategies to improve the quality of the studies and the level of evidence to support the
link between gene response-bioactive compound
Human clinical trial design
# Study design
X A considerable proportion of the studies analyzed in this review were
designed as single arm studies with no appropriate control
group included.
X Many of the randomized controlled studies were designed in a
parallel fashion.
X Studies conducted with an appropriate placebo group were scarce and
most studies used other comparisons: low vs. high doses of the
bioactive compounds. In comparisons carried out between different
diets or foods or food products (complex mix of compounds), it will
be difficult to assign a gene response to a particular bioactive
compound(s).
# Study design
X Gene expression studies in human trials must include appropriate and well-described
control or reference groups to which the intervention group can be compared to [89].
X A crossover design may be preferred since these kind of studies reduce the between
subject variability [89].
X Whenever possible appropriate placebos containing all the compounds in the test
product except for the specific bioactive compound(s) to be investigated should be
applied and described [89]. Alternatively and (o) additionally, different doses (low vs.
high) of the bioactive compound(s) may be used.
# Sample population description
X Most of the studies conducted so far have included limited
information of the volunteers taking part in the study that, in general,
are described as a group (average values, ranges), e.g., mixed cohorts
of men and women, different ranges of age, lifestyle, health status, etc.
X Regarding the health status, about 60% of the gene expression studies
included in this review was carried out in healthy participants only.
# Sample population description
X Future studies should specify as many variables of the test population as possible:
sex, age, ethnic group, lifestyle habits, etc., and, if possible, at the individual level
(e.g., by means of Supplementary Material). This will contribute to the understanding of
gene expression variability and population distribution of gene expression responses and
the factors that may affect it [100].
X More studies in groups with specific diseases are needed. Of especial consideration
should be the individual characterization of the patients investigated, in particular,
with regards to specific molecular targets identified to be implicated in the disease
development and/or in the pathology itself.
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Table 5. Cont.
# Sample size
X In general, the sample size of the control and intervention groups used
in the trials gathered here was small and insufficient to clearly discern
significant and reliable changes in gene expression in human tissue
samples in response to the treatment and/or, to establish the actual
distribution of gene expression changes in the test and
control population.
# Sample size
X An increase of the sample size is needed but, sample size for gene expression studies
may vary depending on the gene, type of sample, and other factors. As we learn more
about gene expression interindividual variability and about the effect sizes (gene
expression changes) in response to dietary bioactives, we shall be able to establish more
appropriate sample sizes for each study.
# Type of intervention
X Mixed compounds or single compounds?
X Foods or extracts (pills)?
X Duration: continued or acute or postprandial?
X Doses of the compounds and products tested are very variable.
Is there an effective dose? Are high doses better than low doses?
# Type of intervention
X More studies using single highly pure compounds are needed in order to unambiguously
prove the potential effects of those compounds or of their derived metabolites in gene
expression in specific cells or tissues.
X Mixed compounds in the form of extracts or complex foods should also be investigated
to understand potential interactions or synergisms occurring between compounds
and/or the effect of matrix on gene expression effects.
X One important issue to clarify is the differences between immediate (rapid) gene
expression responses (short term after intake of the compounds) and those long term
responses (after prolonged consumption) and their relevance in a specific disease.
An additional critical point is the continuity or reversibility of those responses
(epigenetics vs. temporal gene expression regulation).
X Dose-response studies should be implemented to establish the most effective
concentration of a compound to induce a particular gene expression change.
qRT-PCR experimental protocols
# Samples processing and characterization prior to RNA extraction
X This review has evidenced a general lack of information about cell
composition and heterogeneity of the blood cell and tissue samples
used in the different trials.
X There was also little or poorly described information about the
procedures applied for sample extraction and processing as well as
about storage conditions and time elapsed during sample preparation
or storage until further use for RNA extraction.
# Samples processing and characterization prior to RNA extraction
X Knowledge of the heterogeneity and cell composition of the human blood cells and
tissue samples used in the study is necessary. Researchers should include as many
details as possible about the sample characterization.
X Sample preparation protocols can have a large impact on gene expression [4]. It should
be a generalized practice within this type of human studies to include as many details as
possible about the protocols for sample extraction, processing and storage conditions
including the time periods involved in each stage.
Nutrients 2018, 10, 807 25 of 38
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# RNA extraction protocols, yielding and purity
X Most of the studies included in this review have used validated
commercial RNA extraction kits for RNA isolation. Nevertheless,
there is a general lack of detailed description of the protocols and no
indication of important issues such as the inclusion of DNAse
treatment to remove genomic DNA. Although most studies indicate
the measurement of RNA quantity and quality, most reports do not
include data about the RNA yield or the quality results
(e.g., RIN value)
# RNA extraction protocols, yielding and purity
X Future studies looking at gene expression effects of bioactive compounds must include
detailed information of the RNA extraction protocol with indication of genomic DNA
removal, yield of RNA attained in the different tissue samples and specifically indicate
the quality of the RNA samples used in the study by indicating the RIN value. It has
been recommended that values at least above 5.0, that indicate a good total RNA
quality [101], should be used.
# Reference genes selection and stability analysis
X Most of the studies included in this review have used indistinctively
GAPDH, ACTB or 18S rRNA as reference genes for data normalization
in a variety of human cell and tissue samples. There were very few
studies applying a specific criteria or stability analysis to test and
select the most appropriate reference gene.
# Reference genes selection and stability analysis
X It is essential that future studies looking at gene expression effects of bioactive
compounds include a validation assessment of the most suitable reference genes for
normalization of gene expression results. This should be implemented for each tissue
sample and experimental condition tested [91].
Data comparison and presentation
# Comparative strategy.
X Most gene expression changes have been reported using different
comparative strategies. In many of the studies examined here we
found that the expression changes were referred either only to the
comparison between control and treatment groups at the end of the
intervention, or comparing the post- and pre-intervention time points
only for the treated group.
# Comparative strategy.
X For highest evidence of the occurrence of a gene expression change as a consequence of a
particular intervention with a source of bioactive compound(s) it is important
to establish:
⇒ (1) baseline gene expression conditions in the control and treated groups (is there already
any difference or not?),
⇒ (2) gene expression changes in the control volunteers, post-intervention vs. baseline
(is the gene changing in the control group?),
⇒ (3) gene expression changes in the treated group, post-intervention vs. baseline (is the
gene changing in the treated group? Is this change different to the control group?),
⇒ (4) post-intervention comparison between the control and treated groups (can we
corroborate the differences between the two groups?).
X Additional evidence should be provided by dose/response studies, different time-points
and by showing the reversal of the change and the return to the baseline conditions after
a washout period.
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# Results presentation: value of change.
X We found a wide variety of results presentation to indicate the
changes in gene expression, i.e., FC-value, ratio and log2 (ratio), % of
change, mRNA expression levels, arbitrary units, number of mRNA
copies. Very often, the results were presented only in figures from
where the actual average and dispersion values were difficult to infer.
# Results presentation: value of change.
X Although all the indicated ways of presenting gene expression changes used in the
different studies are valid, we propose that standardization to FC-values and % of
change attributed to the intervention with bioactives should be implemented so that
future results from different studies can more easily be compared by means, e.g., of a
meta-analysis. Also, and to improve the clarity of presentation, in addition to figures,
appropriate tables including all these data are strongly recommended.
# Results presentation: data summary and distribution (variability).
X Many studies failed to report whether the gene expression changes
investigated followed a normal distribution and to clearly indicate any
measure of the average and dispersion (variability) employed.
X Those studies that did report gene expression average changes
indicated the final results mostly as the arithmetic mean value
followed by either the SEM or the SD. The median value and IQR
were applied only in a few studies.
X The significance of the changes was generally presented as a p-value
and in most cases p < 0.05 was accepted as significant.
X Overall, group average gene expression changes were presented in
most of the studies included in this review. These average values were
calculated using all the individual results, i.e., adding together,
both upregulation and downregulation changes. Very few studies
included individual data.
# Results presentation: data summary and distribution (variability).
X It is important that information about data (gene expression changes) normality is
provided within the articles as well as to clearly describe the estimators used in the study.
X When providing group average and dispersion gene expression changes, it is probably
best to opt for more robust estimators such as the median and the IQR unless the data
follow a normal distribution. In this latter case, the mean and the SD should be used (the
SEM is not a measure of dispersion) [102].
X As a general tendency, the use of the 95% CI is recommended rather than the p-value.
The 95% CI gives information both about the significance of the results and of the
amount of change, i.e., ‘effect size’ [103].
X Given the high variability in the gene expression responses, the interpretation of
individual results rather than (or in addition to) group average responses should be
implemented [4]. The gene expression upregulation and downregulation results within
the test sample population should be differentiated and the distribution of volunteers
displaying one type or another of response should be indicated. Also, those individuals
not exhibiting a change in the gene should be separately stated. In this regard, it is
important that we progress on the knowledge and understanding of where to establish
the difference between a change (‘effect size’) and a no change (‘no effect’). Up to date,
this is based merely on arbitrary cut-off values. As we progress on the knowledge of the
gene expression regulation in response to bioactive compounds we shall be able to better
establish what a meaningful change may be (‘effect size’) so that we can discern within
the sample population who is responding and who is not responding to the treatment at
the molecular level.
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Other relevant information needed to prove the relationship between the intake of bioactive compounds and gene expression changes and to increase the level of
evidence supporting these molecular changes as a responsive mechanism underlying the health benefits of bioactive compounds in humans
# Bioavailability studies
X Many of the gene expression studies included in this review did not
perform appropriate parallel bioavailability studies of the bioactive
compounds investigated.
# Bioavailability studies
X We need to determine and quantify the specific bioactive compounds and/or derived
metabolites in the cells or tissue samples where the gene expression is going to be
analyzed. The interindividual variability in the bioavailability of these compounds can
have a major impact on the gene expression differences [100].
# Association between gene expression changes and bioactive
compounds and/or metabolites
X Of those studies in which the metabolism and presence of certain
compounds or metabolites was reported, very few indicated to have
found some association (either negative or positive correlation)
between the gene changes detected and the levels of the specific
compound(s).
# Association between gene expression changes and bioactive compounds and/or
metabolites
X We need to search for any relationship(s) between the gene expression changes detected
in the treated group and the presence/concentration of specific bioactive compounds
and/or derived metabolites in the cells and tissue samples and/or in the circulating
blood and/or in urine.
X Additional evidence of the relationship compound-gene change could be provided by
dose/response studies (e.g., larger gene expression changes with increases in the
concentration of a compound) and/or by showing the reversal of the gene expression
changes in the absence of the compound (e.g., after a washout period).
# Changes at the protein/activity level
X Only a few studies attempted to explore the potential association
between the gene expression changes and changes in the protein levels
with only half of them reporting some agreement between
transcription and translation.
# Changes at the protein/activity level
X To further progress on the understanding of the molecular responses and mechanisms
implicated in the health benefits of bioactive compounds we need to implement more
and better studies looking at the protein responses in parallel to the gene expression
studies and try to confirm that the transcription regulation promoted by the specific
bioactive compounds and/or metabolites is translated into active proteins.
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With regards to anti-inflammatory effects, only the intake of EPA + DHA was additionally
associated with the reduction of the expression of IL1β and TNF [67] supporting the notion that these
effects could be related with the induction of PPARG. Recently, it has been demonstrated in obese
children and adolescents that the expression of PPARG is significantly decreased in peripheral blood
mononuclear cells in comparison with gender-matched control subjects, and also negatively correlated
with the levels of plasma fasting glucose, reinforcing that interventions to normalize PPARG expression
may be an effective tool to reduce obesity and associated disorders [104]. Overall, the results reviewed
here provide preliminary evidence that the intake of different foods containing bioactive compounds
may be a potential strategy to activate PPARG in circulating immune cells and contribute to normalize
the levels of plasma glucose or lipids. Whether this molecular event is the direct consequence of the
ingested bioactive compounds or derived metabolites on these cells or a reflection of changes that
may be happening in other tissues such as the liver or adipose tissue is not yet known. There may
be also alternative mechanisms involved in this response such as the potential inhibition by the
bioactive compounds of the digestion and absorption of energy nutrients (fats, carbohydrates) in the
intestine [3]. In support of this hypothesis, it has been shown that the reduction of calorie intake affects
the expression of PPARG in peripheral blood mononuclear cells in rats [105] and in the adipose tissue
of obese women [106] reinforcing this gene as a valuable target of the regulatory metabolic effects of
bioactive compounds that warrants further investigation.
Another gene potentially responsive to the intake of bioactive compounds and associated with
their attributed anti-inflammatory effects is TNF. TNF is a primary mediator of inflammation critically
involved in diverse chronic diseases and thus, any compound(s) with the capacity to modulate
(reduce) this pro-inflammatory cytokine may constitute an important means to battle these disorders.
Many plant derived polyphenols have been shown to inhibit or reduce the production of TNF in various
in vitro cell models such as macrophages, monocytes, leukocytes or adipocytes as well as in animal
models [107]. Nevertheless, the evidence in human studies remains limited. For example, Cur has
been reported to reduce the levels of circulating TNF in a meta-analysis of 8 RCTs although there was
no association with the dose or duration of the supplementation [108]. At the gene expression level,
we have found only one study reporting the lack of effect of turmeric-containing Cur on the expression
of TNF in the gastric antrum [86]. On the other hand, the expression levels of TNF have been reported to
be significantly reduced in isolated mononuclear cells and in blood following intervention with various
other foods and food products containing mixed bioactive compounds, i.e., hazelnuts (polyphenols
and fatty acids) [40], grape products (flavanols and Res) [49,51], and with EPA + DHA [67] (Table 3).
None of these studies, however, described the potential association between the downregulation of
the gene and the specific presence and quantities of bioavailable bioactive compounds or derived
metabolites in the cell and blood samples. In one study, the downregulation of TNF was specifically
associated with the presence of Res in the grape extracts administered to the participants [51]. Res has
been widely investigated for its involvement in the modulation of the inflammatory response and the
cell-specific regulation of gene expression including the downregulation of TNF and other cytokines
in leukocytes [109]. We collected a total of six human studies investigating the effect of Res on gene
expression in different cell and tissues (Table 4) but only two of them included TNF as a target and
both reported the lack of change in the expression levels of this gene in skeletal and adipose tissue,
respectively [74,75]. The evidence in humans supporting TNF expression as a target gene for Res
remains low. A similar situation was observed for SIRT1, a well-established target reported to be
activated by Res in many pre-clinical studies [97]. The protein levels of SIRT1 were found increased
in the muscle of obese volunteers after the intake of Res for 30 days but the authors did not report
specific changes at the gene expression level [110]. Of the studies collected here, the expression levels
of SIRT1 in skeletal muscle [73] and in white blood cells [78] did not appear to be induced after the
intake of Res.
The health-promoting effects of many plant-derived bioactive compounds have been long
attributed to their ability to regulate antioxidant mechanisms in cells either by neutralizing reactive
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species and/or by regulating the expression levels of genes encoding for antioxidant enzymes [111].
One of such genes is GPX1 that encodes for the most abundant and ubiquitously expressed member
of the glutathione peroxidase family and catalyzes the reduction of hydrogen peroxide (H2O2) by
glutathione protecting the cells against oxidative damage. GPX1 expression is altered in several
diseases and its overexpression confers resistance to oxidative damage but it has also been associated
with certain disorders such as high glucose levels [112]. Regulating and maintaining adequate levels
of GPX1 activity may be another important strategy to prevent or reduce the risk of these disorders.
We found four human studies reporting the upregulation of the expression of GPX1 in blood [18,39,40]
and in neutrophils [45] in response to intervention with different sources of bioactive compounds,
i.e., polyphenols from red wine [18] and mixed compounds in hazelnuts [40], Brazil nuts [39] and
fermented papaya [45]. As in previous studies, there was no further evidence of the association with
specific compounds or metabolites or of the translation into higher levels of the protein or of its activity.
The levels of GPX1 mRNA, protein, and activity in tissues is known to be specifically responsive to
dietary quantities of Se [112]. Whether the observed effects may be attributed to any of the bioactive
compounds abundant in the Brazil nuts or to the presence of Se as suggested by Donadio et al., [39] is
not known. More research is needed to further understand the role of GPX1 in oxidative, metabolic and
inflammatory disorders and on the potential regulation of GPX1 expression and activity by natural
bioactive compounds.
Olive oil and broccoli are two of the most investigated food sources of the bioactive compounds,
Tyr and HTyr [113] and SFGluc [114], respectively, with attributed beneficial effects against metabolic,
inflammatory and oxidative disorders (Table 4). At the level of gene expression regulation in humans,
olive oil with a high content of phenolic compounds has been reported to significantly downregulate the
transcription factor EGR1 [26,64] in mononuclear cells. EGR1 has an important role in the inflammatory
response, it is involved in the proliferation, survival and differentiation of lymphocytes B and it has
also been reported as an important hub protein deregulated in inflammatory and cardiovascular
disorders as well as responsive to multiple stimuli [115]. On the other hand, broccoli containing
SFGluc was found to upregulate the oxygenase HMOX1 in blood [26], granulocytes [23] and cells
from nasal lavage [22]. These results suggest that EGR1 and HMOX1 may also be part of the pool of
human gene targets with the potentiality of responding to the intake of bioactive compounds with
attributed anti-inflammatory and cytoprotective effects such as those present in the olive oil and
the broccoli. In support of this, HTyr has been shown to induce the expression of EGR1 in human
promyelocytic leukemia cultured cells [116] and, the oral administration of sulforaphane or SFGluc
promoted the appearance of derived metabolites and the induction of HMOX1 in the breast tissue of
rats and women [117]. Yet again, none of the previous human trials investigated the association of the
regulation of EGR1 or HMOX1 with the presence of Tyr or HTyr or of sulphoraphane metabolites in
the immune cells, blood samples or nasal cells.
Overall, there is still limited evidence for the regulation of specific gene targets in human samples
in response to the intake of bioactive compounds as well as poor agreement with results from previous
pre-clinical studies. Some of the specific critical issues that may be implicated in this lack of accordance
have been previously discussed [118]. Nevertheless, a number of genes (PPARG, TNF, GPX1, EGR1,
HMOX1) are slowly emerging as potential molecular targets commonly responsive to different bioactive
compounds that trigger a combination of interlinked metabolic, inflammatory, and antioxidant
mechanisms that may underlay the health benefits of these compounds. Further studies are needed to
confirm these and other molecular targets of the bioactive compounds. In addition to overcoming the
technical inaccuracies and heterogeneity of the trials carried out so far, the interindividual variability in
the bioavailability of the bioactive compounds and in the responses to these compounds is an essential
feature inherent to humans that also needs to be addressed in future studies [100]. Different factors,
i.e., sex, age, health status or genetic variation can greatly affect gene expression responses and
must be taken into account in the design of future studies so that we can truly discern between the
specific subpopulations of responders (gene up- or down-regulated) and non-responders (no change
Nutrients 2018, 10, 807 30 of 38
in the expression levels). Along these lines, a few studies included in this review have explored
and reported the effects of specific genetic variation in the gene response to the intake of the test
bioactive compounds [39,43,45,87]. It was noted that the expression of GPX1 was upregulated upon
consumption of Brazil nuts only in subjects with a CC genotype at the rs1050450 genetic variant of
this gene [39]. Also, the single nucleotide polymorphisms of NFE2L2 at the positions −617, −651
or −653 appear to be associated with increased expression of NFE2L2 following coffee intake [43].
Other studies, however, did not find a clear genetic effect and thus, the Ser/Ser genotypes of GSTM-1
or hOGG1 did not influence the upregulation of SOD1, CAT, GPX1, OGG1 following intervention
with fermented papaya [45], or the presence of long or short GT genotypes in the promoter region of
HMOX1 did not affect the response to the consumption of Cur [87]. Although these results are very
preliminary, they reflect the importance of including the study of the influence of genetic variation,
as well as of other factors, to contribute to the understanding of the gene expression responses to
dietary bioactive compounds.
7. Concluding Remarks
This compilation of 75 human studies looking at gene expression effects that might be attributed
to dietary bioactive compounds has shown that, most of these trials presented a range of critical
limitations with regards to the study design, experimental settings, data analysis as well as poor
reporting of essential features providing insufficient evidence of the specific reported gene changes.
Although we are aware of the difficulties and economic constraints of implementing all the issues
reviewed here and summarized in Table 5, we need to follow as many of these recommendations as
possible. The aim is to increase the quality of future gene expression studies and the reliability of
the genes selected and investigated as potential targets responsive to specific supplementation with
bioactive compounds. The inclusion of individual gene expression results is relevant to get a more
comprehensive picture of gene expression regulation in response to bioactive compounds without the
need of doing expensive large trials. Obtaining more reliable gene targets in humans will also allow
for better in vitro studies still essential to investigate and understand the cellular and mechanisms of
action of these compounds.
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